官方服务：
资源简介：
Details on switches between bDMARDs.
应用场景：
创建时间：
2018-10-24
相关数据集
Summary of Safety During the Double-Blind, Placebo-Controlled Periods a .
Abbreviations: AE, adverse event; DMARD, disease-modifying antirheumatic drug; IR, inadequate responder; IRR, infusion-related reaction; MTX, methotrexate; OCR200, ocrelizumab 200 mg×2; OCR500, ocreli
NIAID Data Ecosystem50
Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis
Objective To investigate the impact of dose reduction of tumor necrosis factor inhibitor (TNFi) on radiographic progression in ankylosing spondylitis (AS). Methods One hundred and sixty-five patients
NIAID Data Ecosystem40
Baseline characteristics and laboratory findings of patients starting their first TNF-α inhibitor according to whether they subsequently switched or not.
TNF, tumor necrosis factor; BMI, body mass index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST, aspartate aminotransfer
NIAID Data Ecosystem30
Selected patient characteristics at first-time b/tsDMARD.
Selected patient characteristics at first-time b/tsDMARD.
NIAID Data Ecosystem50
Table_2_Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes.DOCX
Background: Aim of this study was to search for any difference in the outcome of patients with adult onset Still's disease (AOSD) treated with anakinra (ANK) in relation with the interval between dise
NIAID Data Ecosystem30
